These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 16424737)

  • 21. Drug for severe sepsis is withdrawn from market, fails to reduce mortality.
    Mitka M
    JAMA; 2011 Dec; 306(22):2439-40. PubMed ID: 22166598
    [No Abstract]   [Full Text] [Related]  

  • 22. Drotrecogin alfa on trial.
    Tillotson GS
    Lancet Infect Dis; 2009 Jan; 9(1):2-3. PubMed ID: 19095188
    [No Abstract]   [Full Text] [Related]  

  • 23. Coagulopathy and the role of recombinant human activated protein C in sepsis and following polytrauma.
    Dahabreh Z; Dimitriou R; Chalidis B; Giannoudis PV
    Expert Opin Drug Saf; 2006 Jan; 5(1):67-82. PubMed ID: 16370957
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk-benefit analysis for drotrecogin alfa (activated).
    Schein RM; Kinasewitz GT
    Am J Surg; 2002 Dec; 184(6A Suppl):S25-38. PubMed ID: 12521615
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reassessing recombinant human activated protein C for sepsis: time for a new randomized controlled trial.
    Eichacker PQ; Danner RL; Suffredini AF; Cui X; Natanson C
    Crit Care Med; 2005 Oct; 33(10):2426-8. PubMed ID: 16215410
    [No Abstract]   [Full Text] [Related]  

  • 26. Recombinant human activated protein C.
    Hughes M
    Int J Antimicrob Agents; 2006 Aug; 28(2):90-4. PubMed ID: 16837170
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of drotrecogin alfa (activated) for the therapy of surgical patients with severe sepsis.
    Barie PS; Hydo LJ; Shou J; Eachempati SR
    Surg Infect (Larchmt); 2006; 7 Suppl 2():S77-80. PubMed ID: 16895513
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drotrecogin alfa (activated) in severe sepsis.
    Friedrich JO
    N Engl J Med; 2006 Jan; 354(1):94-6; author reply 94-6. PubMed ID: 16394311
    [No Abstract]   [Full Text] [Related]  

  • 29. Drotrecogin alfa: new preparation. For some cases of severe sepsis?
    Prescrire Int; 2003 Apr; 12(64):55-7. PubMed ID: 12674116
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drotrecogin alfa (activated) in severe sepsis.
    Baillie JK; Murray G
    N Engl J Med; 2006 Jan; 354(1):94-6; author reply 94-6. PubMed ID: 16395834
    [No Abstract]   [Full Text] [Related]  

  • 31. Drotrecogin alfa (activated) administration: too many subgroups.
    Carlet J
    Crit Care Med; 2003 Oct; 31(10):2564; author reply 2564-5. PubMed ID: 14530774
    [No Abstract]   [Full Text] [Related]  

  • 32. Drotrecogin alfa (activated) in severe sepsis.
    LaRosa SP
    N Engl J Med; 2006 Jan; 354(1):94-6; author reply 94-6. PubMed ID: 16395833
    [No Abstract]   [Full Text] [Related]  

  • 33. The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis.
    Angus DC; Laterre PF; Helterbrand J; Ely EW; Ball DE; Garg R; Weissfeld LA; Bernard GR;
    Crit Care Med; 2004 Nov; 32(11):2199-206. PubMed ID: 15640631
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis.
    Barton P; Kalil AC; Nadel S; Goldstein B; Okhuysen-Cawley R; Brilli RJ; Takano JS; Martin LD; Quint P; Yeh TS; Dalton HJ; Gessouron MR; Brown KE; Betts H; Levin M; Macias WL; Small DS; Wyss VL; Bates BM; Utterback BG; Giroir BP
    Pediatrics; 2004 Jan; 113(1 Pt 1):7-17. PubMed ID: 14702440
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activated protein C for the treatment of severe sepsis.
    Houston G; Cuthbertson BH
    Clin Microbiol Infect; 2009 Apr; 15(4):319-24. PubMed ID: 19416303
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recombinant human activated protein C for severe sepsis.
    Kapur S; Kupfer Y; Tessler S
    N Engl J Med; 2001 Jul; 345(3):219-20; author reply 220-1. PubMed ID: 11463021
    [No Abstract]   [Full Text] [Related]  

  • 37. An economic evaluation of activated protein C treatment for severe sepsis.
    Manns BJ; Lee H; Doig CJ; Johnson D; Donaldson C
    N Engl J Med; 2002 Sep; 347(13):993-1000. PubMed ID: 12324556
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recombinant human activated protein C sentenced to the death of a thousand cuts?
    O'Brien JM
    Crit Care Med; 2007 Jun; 35(6):1609-10. PubMed ID: 17522532
    [No Abstract]   [Full Text] [Related]  

  • 39. Corticosteroids and human recombinant activated protein C for septic shock.
    Colin G; Annane D
    Clin Chest Med; 2008 Dec; 29(4):705-12, x. PubMed ID: 18954704
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Activated protein C--recent addition to therapy of sepsis].
    Gårdlund B; Sjölin J
    Lakartidningen; 2003 Jun; 100(26-27):2292-6. PubMed ID: 12872375
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.